Latest:
Dr Parma on Survival Outcomes With Immunotherapy in Patients With NSCLC Brain Metastases
Mitchell Parma, MD, discusses an analysis of survival benefit with immunotherapy in patients with NSCLC brain metastases.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Michael Dennis, MD
Michael Dennis, MD, is a physician at Dana-Farber Cancer Institute; as well as an instructor in medicine at Harvard Medical School
Latest:
Long-Term Data Underscore the Enduring Efficacy of PD-1 Inhibition in Nasopharyngeal Carcinoma: With Michael Dennis, MD
Dr Dennis discusses guidelines for nasopharyngeal carcinoma management and data with first-line toripalimab plus chemotherapy in metastatic disease.
Matthias Preusser, MD
Latest:
Q&A: Final Questions on Glioblastoma and Neuroimaging
Nathalie Albert, MD, and Matthias Preusser, MD, address audience questions and share their insights on promising and anticipated advancements in neuroimaging techniques, highlighting the potential impact of these emerging strategies on the diagnosis, monitoring, and treatment of glioblastoma.
Sepideh Gholami, MD, FACS, UC Davis Comprehensive Cancer Center
Latest:
ASCO GI 2021: MRD Detection With ctDNA From Assays
Expert physicians discuss data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) 2021 annual meeting, regarding minimal residual disease (MRD) detection with ctDNA (circulating tumor DNA) from personalized assays in stage II and III patients with colorectal cancer.
Jade E. Jones, MD
Jade E. Jones, MD, is a medical oncologist at Winship Cancer Institute and assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine.
Latest:
Dr Jones on the Implications of Data from ASCENT-04 for First-Line PD-L1+ TNBC Management
Jade E. Jones, MD, discusses the importance of identifying the most effective first-line treatment regimen for PD-L1–positive TNBC.
Alicia Morgans, MD, MPH
Alicia Morgans, MD, MPH, is a
Latest:
Dr Morgans on the Rationale for Evaluating Darolutamide Plus ADT in High-Risk Biochemical Recurrence of Prostate Cancer
Alicia Morgans, MD, MPH, discusses the background of darolutamide plus ADT in patients with prostate cancer with high-risk biochemical recurrence.
Stephen Liu, MD
Stephen Liu, MD, is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.
Latest:
Resistance Mechanisms and Molecular Testing in ALK Inhibitor–Treated NSCLC
Panelists discuss mechanisms of acquired resistance to ALK inhibition and how molecular testing guides sequencing strategies.
Wendell Naumann, MD
Latest:
Future of Gynecologic Oncology: Integrating Antibody-Drug Conjugates and Novel Combinations Into the IO Sequencing Paradigm for Advanced EC
Panelists discuss how future therapies, such as antibody-drug conjugates (ADCs) and novel combination therapies, could enhance immuno-oncology (IO) sequencing by offering more targeted options for patients who have progressed on initial IO therapies, while addressing resistance mechanisms and improving overall treatment outcomes.